SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-176190
Filing Date
2023-06-27
Accepted
2023-06-27 16:34:31
Documents
13
Period of Report
2023-06-21
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d506849d8k.htm   iXBRL 8-K 38090
2 EX-3.1 d506849dex31.htm EX-3.1 121668
  Complete submission text file 0001193125-23-176190.txt   315493

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA howl-20230621.xsd EX-101.SCH 2848
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE howl-20230621_lab.xml EX-101.LAB 19483
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE howl-20230621_pre.xml EX-101.PRE 12152
7 EXTRACTED XBRL INSTANCE DOCUMENT d506849d8k_htm.xml XML 3680
Mailing Address 200 TALCOTT AVENUE 2ND FLOOR WATERTOWN MA 02472
Business Address 200 TALCOTT AVENUE 2ND FLOOR WATERTOWN MA 02472 617-952-0555
Werewolf Therapeutics, Inc. (Filer) CIK: 0001785530 (see all company filings)

IRS No.: 823523180 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40366 | Film No.: 231047848
SIC: 2834 Pharmaceutical Preparations